In contrast, in the CRYSTAL study, a correspondence was reported between the fraction of KRAS mutated tumor cells and cetuximab efficacy, with a benefit of cetuximab combined chemotherapy in patients with a low prevalence of KRAS mutations (0.1% to 0.5%) [228,229]. Here, KRAS is linked to neoplasm.